Therapy of Chronic Lymphocytic Leukaemia with Purine Nucleoside Analogues

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Drugs & Aging

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00002512-200522120-00002PMID 16363884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fludarabine

  2012cited by this paper
• Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia

  2012cited by this paper
• Application of population pharmacokinetics to cladribine

  2005cited by this paper
• Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment

  2005cited by this paper
• Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1).

  2005cited by this paper
• Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

  2005cited by this paper
• Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

  2005cited by this paper
• Richter syndrome

  2005cited by this paper
• Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells

  2005cited by this paper
• Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

  2005cited by this paper
• Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

  2005cited by this paper
• Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells

  2005cited by this paper
• Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.

  2005cited by this paper
• Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

  2005cited by this paper
• Stem cell transplantation for chronic lymphocytic leukaemia

  2005cited by this paper
• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

  2005cited by this paper
• The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil.

  2005cited by this paper
• Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

  2004cited by this paper
• Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.

  2004cited by this paper
• Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.

  2004cited by this paper
• Cladribine Alone or in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone as First Line Treatment in Chronic Lymphocytic Leukemia: An Early Report of Prospective Randomized Study.

  2004cited by this paper
• Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies

  2004cited by this paper
• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

  2004cited by this paper
• Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

  2004cited by this paper
• CD26 Expression Correlates with a Reduced Sensitivity to 2′-Deoxycoformycin-Induced Growth Inhibition and Apoptosis in T-Cell Leukemia/Lymphomas

  2004cited by this paper
• Pentostatin (Nipent®) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia

  2004cited by this paper
• Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway

  2004cited by this paper
• Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.

  2004cited by this paper
• Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.

  2004cited by this paper
• The clinical and epidemiological burden of chronic lymphocytic leukaemia.

  2004cited by this paper
• Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

  2004cited by this paper
• Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.

  2004cited by this paper
• Towards the pharmacotherapy of hairy cell leukaemia

  2004cited by this paper
• Treatment of Resistant/Relapsing Chronic Lymphocytic Leukemia with a Combination Regimen Containing Deoxycoformycin and Rituximab

  2004cited by this paper
• Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• The role of stem cell transplantation in chronic lymphocytic leukemia.

  2004cited by this paper
• Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

  2004cited by this paper
• Treatment of T-cell non-hodgkin’ lymphoma

  2004cited by this paper
• Nucleoside transporters in chronic lymphocytic leukaemia

  2004cited by this paper
• Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)

  2004cited by this paper
• Second Malignancies and Richter's Syndrome in Patients with Chronic Lymphocytic Leukemia

  2004cited by this paper
• Mechanism of action of purine analogues in chronic lymphocytic leukaemia

  2003cited by this paper
• Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias

  2003cited by this paper
• Conventional Dose Fludarabine-based Regimens are Effective but have Excessive Toxicity in Elderly Patients with Refractory Chronic Lymphocytic Leukemia

  2003cited by this paper
• Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia

  2003cited by this paper
• Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

  2003cited by this paper
• A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211

  2003cited by this paper
• Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

  2003cited by this paper
• Combined Fludarabine and Rituximab for Low Grade Lymphoma and Chronic Lymphocytic Leukemia

  2003cited by this paper
• Hemostasis, Thrombosis, and Vascular Biology

  2003cited by this paper
• Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

  2003cited by this paper
• Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.

  2002cited by this paper
• Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma

  2002cited by this paper
• Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.

  2002cited by this paper
• Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

  2002cited by this paper
• Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.

  2002cited by this paper
• Re‐treatment with cladribine‐based regimens in relapsed patients with B‐cell chronic lymphocytic leukemia

  2002cited by this paper
• Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

  2002cited by this paper
• Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.

  2002cited by this paper
• Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

  2002cited by this paper
• Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia

  2002cited by this paper
• Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

  2002cited by this paper
• Non-Hodgkin's lymphoma: the evolving role of purine analogues.

  2002cited by this paper
• Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro

  2002cited by this paper
• Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

  2002cited by this paper
• Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

  2002cited by this paper
• Cellular and Clinical Pharmacology of Fludarabine

  2002cited by this paper
• Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia

  2002cited by this paper
• Oral cladribine for B‐cell chronic lymphocytic leukaemia: report of a phase II trial with a 3‐d, 3‐weekly schedule in untreated and pretreated patients, and a long‐term follow‐up of 126 previously untreated patients

  2002cited by this paper
• Waldenström's macroglobulinaemia.

  2002cited by this paper
• Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia

  2001cited by this paper
• Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria.

  2001cited by this paper
• Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

  2001cited by this paper
• Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre‐treated patients with advanced indolent lymphoid malignancies

  2001cited by this paper
• Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.

  2001cited by this paper
• Management of the Chronic Leukemias: Special Considerations in the Elderly Patient. Part I. Chronic Lymphocytic Leukemias

  2001cited by this paper
• Second Primary Tumors and Immune Phenomena After Fludarabine or 2-Chloro-2′-Deoxy adenosine Treatment

  2001cited by this paper
• Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

  2001cited by this paper
• Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

  2001cited by this paper
• Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine.

  2001cited by this paper
• Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

  2001cited by this paper
• The bioavailability of oral fludarabine phosphate is unaffected by food.

  2001cited by this paper
• Infectious complications of purine analog therapy

  2001cited by this paper
• Cladribine in the Treatment of Chronic Lymphocytic Leukemia

  2001cited by this paper
• Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status

  2001cited by this paper
• Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair

  2000cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.

  2000cited by this paper
• Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

  2000cited by this paper
• Cladribine with or without prednisone in the treatment of previously treated and untreated B‐cell chronic lymphocytic leukaemia — updated results of the multicentre study of 378 patients

  2000cited by this paper
• Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.

  2000cited by this paper
• Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388.

  2000cited by this paper
• Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP)

  2000cited by this paper
• When and how to treat chronic lymphocytic leukemia.

  2000cited by this paper
• Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.

  2000cited by this paper
• Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.

  2000cited by this paper
• Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

  2000cited by this paper
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• Nucleotide Requirements for the in Vitro Activation of the Apoptosis Protein-activating Factor-1-mediated Caspase Pathway*

  2000cited by this paper

• Pneumonia in Transplant Recipients: A Comprehensive Review of Diagnosis and Management

  2024cites this paper
• A decade of chronic lymphocytic leukaemia therapy in Germany: Real‐world treatment patterns and outcomes (2010–2022)

  2024cites this paper
• Real-world studies on B-cell malignancies

  2020cites this paper
• Cutaneous manifestations of B-cell chronic lymphocytic leukemia

  2020cites this paper
• Targeted Therapy in Chronic Lymphocytic Leukemia

  2019cites this paper
• Chronic lymphocytic leukaemia

  2017cites this paper
• Combined chronic lympholeukosisand Hodgkin lymphoma

  2017cites this paper
• Cutaneous Richter syndrome: a better place to transform?

  2015cites this paper
• Hypoxia‐induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease

  2013cites this paper
• Current and Emerging Treatments for Chronic Lymphocytic Leukaemia

  2012cites this paper
• Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.

  2011cites this paper
• Therapeutic management of chronic lymphocytic leukaemia: state of the art and future perspectives.

  2011cites this paper
• Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX‐2

  2011cites this paper
• Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation

  2011cites this paper
• Znaczenie rokownicze wybranych parametrów klinicznych i laboratoryjnych u chorych na przewlekłą białaczkę limfocytową B-komórkową

  2011cites this paper
• The cladribine conundrum: deciphering the drug's mechanism of action

  2010cites this paper
• TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.

  2009cites this paper
• Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.

  2009cites this paper
• Human Nucleoside Transporters: Biomarkers for Response to Nucleoside Drugs

  2009cites this paper
• Targeted therapy for chronic lymphocytic leukemia

  2009cites this paper
• Chapter 2: Ring-Expanded (‘Fat‘) Purines and their Nucleoside/Nucleotide Analogues as Broad-Spectrum Therapeutics

  2009cites this paper
• Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia

  2008cites this paper
• The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs

  2007cites this paper
• Malignant lymphomas in the elderly: a single institute experience highlights future directions.

  2007cites this paper
• Recent progress in the management of chronic lymphocytic leukemia.

  2007cites this paper
• Presence of the anti-leukemic nucleotide analog, 2-chloro-2'-deoxyadenosine-5'-monophosphate, in a promoter sequence alters DNA binding of TATA-binding protein (TBP).

  2007cites this paper
• Skin lesions in chronic lymphocytic leukemia

  2007cites this paper
• Influence of cladribine alone and in combinaton with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia

  2007cites this paper
• Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

  2007cites this paper
• Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma

  2006cites this paper
• Treatment Options for Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

  2006cites this paper
• Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

  2006cites this paper
• Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

  2006cites this paper